Executive Summary

Investment Thesis: Trulieve ($TCNNF) is trading well below prior highs after a deep reset in 2025, yet the business shows improving fundamentals. Management reported narrowing losses, 60% gross margins and record cash flow in FY2025, and the company carries a strong cash position relative to its size. Valuation metrics, notably an EV/EBITDA around 4.8, suggest the market is pricing in continued execution risk rather than the operational momentum that emerged last year.

Current Price: $5.23 | Key Metric: EV/EBITDA ~4.84 | Stance: BULLISH

Company Overview

Trulieve Cannabis Corp ($TCNNF) is a vertically integrated cannabis operator focused on cultivation, processing and retail distribution across multiple U.S. states where medical and adult-use cannabis markets operate. The company also serves ancillary pharmaceutical and wellness channels through branded products and wholesale relationships.

Key Products & Competitive Position

Core Business: Retail dispensaries, wholesale distribution and vertically integrated cultivation and processing.
Key Products: Flower, extracts, vape cartridges, tinctures and branded packaged goods for adult-use and medical customers.
Competitive Moat: Large retail footprint in key U.S. states, integrated supply chain allowing margin capture, and recognizable consumer brands that drive repeat purchase.

Recent Developments

FY2025 results showed widening operational leverage with a reported 60% gross margin and record cash flow generation. Management highlighted narrowing net losses and improved free cash flow, while the company maintained a strong liquidity position with about $255.5M in cash. Analysts are noting that small regulatory shifts and valuation repricing could materially change the investment story over the next 12 months.

Financial Snapshot

Market Cap$1.52B

P/E RatioN/A

52-Week Range$4.30 - $16.35

Dividend Yield0.0%

EPS (TTM)$-0.61

ROE-9.65%

Revenue & Earnings Trends

Revenue (TTM) is roughly $1.18B, while net income for the trailing twelve months shows a loss near $-110.8M. Despite the headline loss, operating performance improved through FY2025 with gross margins expanding to about 60% and a strong levered free cash flow of approximately $169.8M. That suggests the business is converting sales to cash more efficiently than earlier periods.

EPS remains negative at -$0.61 on a TTM basis, but analysts and management highlight a narrowing loss profile and improved operating leverage. Trending metrics point to progress from heavy restructuring and optimization initiatives implemented over the last 18 months.

Balance Sheet Highlights

Trulieve has a conservative near-term liquidity position. Total cash is about $255.5M and the current ratio sits at 4.43, indicating ample short-term coverage of liabilities. Reported total debt to equity is elevated at roughly 49.5% but manageable given the company’s cash flows. The balance sheet supports continued investment in retail and supply chain, while providing a buffer against cyclical headwinds.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDA4.84vs Historical: higher

P/S Ratio~1.07vs Peers: attractive

Historical Comparison

TCNNF traded substantially higher during 2024 and early 2025 when the stock hit a 52-week high of $16.35. Current multiples are meaningfully compressed compared with that period. EV/EBITDA near 4.8 and P/S around 1.1 are lower than many higher-growth cannabis peers, reflecting the market discount for execution and regulatory risk despite improving underlying cash generation.

Fair Value Estimate

Using a blended approach that blends a conservative DCF like framework with EV/EBITDA peer multiple normalization, a mid-cycle fair value range sits around $8.50 to $12.00 per share. A central fair value estimate of roughly $10.00 per share assumes sustained margin retention, modest revenue growth in U.S. markets and steady deleveraging of operating expenses. That implies a potential upside from current levels, but the gap depends heavily on execution and regulatory clarity.

Competitive Landscape

Market Position

Market Share: Estimated mid-single digits in U.S. market footprint | Ranking: Top 5 vertically integrated U.S. MSO in retail footprint and revenue scale

Key Competitors

$CURLFLarge multi-state operator with broad retail presence

$CRLBFVertically integrated MSO focused on brand scale

$TLRYLegacy cannabis operator with national distribution and brand investments

Competitive Advantages

Moat 1: Retail density in core states, which supports brand recognition and repeat customers.
Moat 2: Integrated supply chain enabling higher gross margins than many peers.
Moat 3: Strong cash generation and liquidity that provide optionality for investment or acquisitions during cyclical stress.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 misses

Recent Earnings History

Q4 2025Revenue and cash flow beat estimatesBEAT

Q3 2025Positive margin progression vs prior quartersBEAT

Q2 2025Execution disruptions and higher costsMISS

Q1 2025Core revenue growth and improved retail compsBEAT

Guidance Trend

Management has signaled tightening guidance ranges and a focus on cash generation rather than top-line growth at all costs. Analysts have adjusted models to reflect narrowing losses and stronger FCF, but guidance remains contingent on state-level demand and regulatory developments.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 2 Buy: 10 Hold: 1 Sell: 0

Price Targets

Low: $6.00
Mean: $11.50 (+120% upside)
High: $16.00

Recent Analyst Actions

Most analysts have upgraded earnings and cash flow estimates following FY2025 results that showed margin improvement and strong free cash flow. The tone from coverage is constructive, with multiple upgrades to target prices based on the improved operating cadence and the potential for market re-rating if regulatory headwinds ease.

Recent News & Catalysts

Key Developments

FY2025 Results: Reported 60% gross margin and record cash flow, both cited as evidence of operational improvement.
Analyst Revisions: Several firms raised estimates and targets after Q4 2025, shifting consensus to Strong Buy.
State-level Policy Shifts: Ongoing, incremental policy and regulatory changes in U.S. cannabis markets are being monitored, with subtle shifts potentially changing the outlook for national operators.

Upcoming Catalysts

Next Earnings: Expected 2026-05-05 After Market | Key Events: Q1 2026 results, management commentary on demand trends, guidance and capital allocation; any state-level regulatory announcements that affect retail operations

Technical Outlook

Current Price: $5.23 vs 52-Week High: $16.35 (-68% from high)

Trend Analysis

Price action shows a steep downtrend from the December 2025 high into early 2026, followed by a period of consolidation and heightened intraday volatility. Today's nearly 10% drop increased downside momentum, but the stock remains above its 52-week low of $4.30. Momentum indicators have flashed oversold conditions at multiple points this year, which can lead to sharp mean-reversion rallies in high-beta names like TCNNF.

Key Levels

Resistance: $6.50, $8.00, $10.00
Support: $5.00, $4.30, $3.50

Bull vs Bear Case

Bull Case

Catalyst 1: Continued margin retention and high gross margins, driving robust free cash flow and reducing the valuation discount.
Catalyst 2: Regulatory improvements or clearer federal policy paths that unlock multiple re-rating for MSOs.
Catalyst 3: Strategic M&A or share consolidation using strong cash flows to create scale and accretive growth.

Bull Target: $15.00 (+187%)

Bear Case

Risk 1: Regulatory uncertainty at state or federal levels that restricts market expansion or increases compliance costs.
Risk 2: Demand softness or retail footfall declines that compress margins and reverse recent FCF gains.
Risk 3: High stock volatility and funding needs that could force dilutive capital raises if cash generation slows.

Bear Target: $4.00 (-23%)

Risks to Consider

Valuation Risk: While EV/EBITDA looks attractive, multiples reflect execution and regulatory uncertainty. If fundamentals deteriorate, the multiple could compress further.
Competitive Risk: Market is crowded with MSOs competing on price and retail expansion, which could pressure margins in some states.
Macro Risk: High beta and consumer discretionary exposure mean TCNNF can suffer outsized declines in risk-off environments.
Execution Risk: Maintaining margin expansion across new retail openings and supply chain scale is challenging and requires disciplined cost control.

Bottom Line

Investment Verdict: BULLISH

Trulieve is a cash-generative, vertically integrated MSO trading at materially discounted multiples relative to its recent peak. Analysts remain constructive and FY2025 demonstrated real operational progress. That said, the path to market re-rating depends on continued margin retention, state-level demand resilience and clearer regulatory outcomes, all of which remain uncertain.

Action Items for Investors

Long-term investors: Monitor earnings cadence, free cash flow consistency and any federal or major state policy shifts, since these drive long-term revaluation rather than short-term noise.
Short-term traders: Watch near-term technical levels and volatility, and consider earnings dates and news flow when sizing positions, as the stock can gap sharply on sentiment changes.
Risk management: Track cash runway and any capital raises, set position sizing based on heightened beta, and use stop limits or hedges if downside risk expands.

What to Watch This Week

Pre-earnings positioning ahead of Q1 2026 expected 2026-05-05 after market, and any preview commentary from management.
State-level regulatory developments that could affect retail operations or wholesale distribution.
Analyst model revisions and any changes to consensus price targets following fresh guidance or interim operational updates.

Can Trulieve sustain the cash-flow momentum and convert it into durable profitability? Will regulatory shifts provide the catalyst for a multiple expansion? Keep an eye on the next earnings release and state policy items, because those will likely decide whether the market's discount narrows or widens.

TCNNF: Cash-flow Strength Meets Discounted Valuation